SOLICITATION NOTICE
B -- Services for Stavanger Nested Case-Control Study of Preeclampsia
- Notice Date
- 7/15/2005
- Notice Type
- Solicitation Notice
- NAICS
- 541710
— Research and Development in the Physical, Engineering, and Life Sciences
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-50088-NE
- Response Due
- 7/29/2005
- Archive Date
- 8/13/2005
- Description
- The National Cancer Institute (NCI), Laboratory of Biosystems and Cancer (LBC), Center for Cancer Research (CCR) plans to procure, on a sole source basis, data entry and file development from the initial first year of the prospective follow-up study to the Stavanger Nested Case-Control Study of Preeclampsia with Norwegian University of Science and Technology, School of Medicine, NO-7489 Trondheim, Norway. The acquisition is being conducted under the simplified acquisition procedures authorized in FAR Part 13. The North American Industry Classification System Code is 541710 and the business size standard is 500 employees. Background: The Laboratory of Biosystems and Cancer, Center for Cancer Research, NCI, requires the data entry of and file development from the first year of follow-up study of questionnaires and other data collection techniques to the 1993 birth cohort of the study known as: The influence of preeclampsia on hormonal and anthropometric status in boys and girls at 10 and 13 years of age: Follow-up of the Stavanger population?based nested case-control study, (heretofore known as the Puberty Follow-Up Study). The ultimate purpose of this research project is to explore the biological mechanisms underlying why women who suffered from preeclampsia during pregnancy and their offspring are at significantly reduced risk of breast cancer (in mothers and daughters of that pregnancy) while the male offspring are at the lowest risk of prostate cancer identified in the literature. The information collected during the first year of data collection will need to be keyed, entered, and developed in an analytic file for analysis of the major study objectives. Given the large sample size of 1,000 parent-offspring pairs in the original birth study, there is the opportunity to have the statistical power to compute hormonal and other growth factor differences in the study population. Dr. Lars Vatten was the primary author to the research based in the Rogaland Hospital in Stavanger, Norway of the population-based study of women diagnosed with preeclampsia in pregnancy and their offspring and a comparable set of normotensive controls. His analysis of the original birth study identified significant growth retardation in newborns of preeclamptic in contrast with newborns of normotensive mothers as well as hormonal differences in the cord blood of the offspring of the two pregnancies. These hormones are associated with reduced risk of breast cancer in animal models and in human epidemiologic research. Dr. Vatten and his team therefore have the experience with the study cohort and have collaborated with the Rogaland Central Hospital to develop the file and link to other available registries in Norway. This is the only population-based study to date of preeclampsia and these women represent all women, who were diagnosed with preeclampsia in pregnancy in the birth years from 1993 through 1995 who resided in the Stavanger area in Norway. The NCI has the opportunity to conduct a follow-up of these mothers and children, linking with the original study database. The questionnaire items focus on dietary intake during the index pregnancy and since the birth of the index child, lifestyle and demographic characteristics, family history of cancer, and family history of reproductive disease, including preeclampsia in the mother?s and biological father?s families. Period of Performance: estimated three months. The Norwegian University of Science and Technology, School of Medicine is the only known source to the NCI that can provide the aforementioned requirements. The Investigator has been involved in the original birth study and has worked for many years with the Medical Director of The Rogaland Central Hospital. Their insights from the original study as well as their scientific leadership in the area of preeclampsia provide extraordinary knowledge and experience in the Norwegian linked birth-cancer registry system, the public health record system, and in this particular study population. They have worked with the study data sets over the years and can thereby lead a team in the data analysis of the follow-up study. This notice of intent is not a request for competitive quotation. However, if any interested party believes it can meet the above requirements, it may submit a statement of capabilities. The capability statement and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can fully meet the requirements herein. Capability statements must be received in the contracting office by 1:00 PM EDT on July 29, 2005. If you have any questions, please submit them in writing via electronic mail to Karen Gardner, Contract Specialist at gardnerka@mail.nih.gov or by fax 301-402-4513. A determination by the Government not to compete this proposed requirement based on responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered with the Central Contractor Registration (CCR) at www.ccr.gov and the online Representations and Certifications Applications (ORCA) at http://orca.bpn.gov.
- Place of Performance
- Address: Norway
- Country: Norway
- Country: Norway
- Record
- SN00848158-W 20050717/050715211914 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |